We developed CardioScore based on over ten years’ worth of Genome Wide Association Studies (GWAS) which combined allow us to understand the genetic component of coronary artery disease (CAD) in unprecedented detail. GWAS use datasets of hundreds of thousands of people and have identified more than 1.9 million genetic variants that can be used to predict CAD risk.
CardioScore uses our proprietary pipeline with an individual’s genetic data at around 750,000 variants. First, these variants are used to impute a further several million genetic variants across the genome. Next, we perform stringent industry-standard quality control to ensure high quality data is used to compute a Polygenic Risk Score for cardiovascular disease risk. More information can be found in our white paper.
We have validated the predictive power of CardioScore in more than 400,000 individuals from the UK Biobank, showing that CardioScore has the highest predictive power (or more formally the highest C-index) when compared to traditional cardiovascular risk factors.